Journal of Oncology

Research Article

GJA1 rs2071165 A > G Variant Increased Gastric Cancer Risk in Females of Northwest China: A Case-Control Study

Table 2

Stratification analyses for the association between genetic polymorphism and gastric cancer susceptibility.


	Genotype	Control	Case	OR (95% CI)		OR (95% CI)	²

Age¹
<55	rs2071165
	GG	235	133	1.00	0.36	1.00	0.32
	AG	173	98	1.00 (0.72–1.38)		1.02 (0.73–1.42)
	AA	21	19	1.60 (0.83–3.08)		1.66 (0.86–3.22)
	AG/AA	194	117	1.06 (0.78–1.45)	0.71	1.09 (0.80–1.49)	0.59
	rs4530741
	CC	127	84	1.00	0.37	1.00	0.46
	AC	213	122	0.87 (0.61–1.23)		0.89 (0.62–1.27)
	AA	90	43	0.72 (0.46–1.14)		0.75 (0.47–1.18)
	AC/AA	303	165	0.82 (0.59–1.15)	0.26	0.84 (0.60–1.18)	0.33
	rs6874309
	AA	358	215	1.00	0.63	1.00	0.68
	AT	68	33	0.81 (0.52–1.27)		0.83 (0.53–1.30)
	TT	4	2	0.83 (0.15–4.58)		0.76 (0.14–4.27)
	AT/TT	72	35	0.81 (0.52–1.25)	0.34	0.82 (0.53–1.28)	0.39

≥55	rs2071165
	GG	188	249	1.00	0.44	1.00	0.36
	AG	115	158	1.04 (0.76–1.41)		1.15 (0.81–1.63)
	AA	24	22	0.69 (0.38–1.27)		0.70 (0.35–1.39)
	AG/AA	139	180	0.98 (0.73–1.31)	0.88	1.07 (0.77–1.49)	0.69
	rs4530741
	CC	123	142	1.00	0.22	1.00	0.7
	AC	138	208	1.31 (0.94–1.80)		1.15 (0.80–1.66)
	AA	66	79	1.04 (0.69–1.56)		1.00 (0.63–1.59)
	AC/AA	204	287	1.22 (0.90–1.65)	0.2	1.11 (0.79–1.55)	0.56
	rs6874309
	AA	277	354	1.00	0.29	1.00	0.48
	AT	46	73	1.24 (0.83–1.85)		1.18 (0.75–1.85)
	TT	4	2	0.39 (0.07–2.15)		0.38 (0.05–3.02)
	AT/TT	50	75	1.17 (0.79–1.74)	0.42	1.13 (0.72–1.75)	0.6

Gender³
Male	rs2071165
	GG	262	305	1.00	0.35	1.00	0.74
	AG	194	191	0.85 (0.65–1.10)		0.92 (0.69–1.22)
	AA	33	30	0.78 (0.46–1.32)		0.84 (0.47–1.48)
	AG/AA	227	221	0.84 (0.65–1.07)	0.16	0.91 (0.69–1.19)	0.48
	rs4530741
	CC	150	167	1.00	0.77	1.00	0.65
	AC	242	263	0.98 (0.74–1.29)		1.04 (0.76–1.41)
	AA	97	95	0.88 (0.61–1.26)		0.87 (0.59–1.29)
	AC/AA	339	358	0.95 (0.73–1.24)	0.70	0.99 (0.74–1.32)	0.93
	rs6874309
	AA	406	441	1.00	0.45	1.00	0.43
	AT	78	83	0.98 (0.70–1.37)		0.89 (0.62–1.29)
	TT	5	2	0.37 (0.07–1.91)		0.33 (0.05–2.24)
	AT/TT	83	85	0.94 (0.68–1.31)	0.73	0.86 (0.60–1.24)	0.43

Female	rs2071165
	GG	161	77	1.00	0.1	1.00	0.084
	AG	94	66	1.47 (0.97–2.22)		1.49 (0.98–2.26)
	AA	12	11	1.92 (0.81–4.54)		2.04 (0.85–4.87)
	AG/AA	106	77	1.52 (1.02–2.27)	0.04	1.55 (1.03–2.32)	0.034
	rs4530741
	CC	100	60	1.00	0.52	1.00	0.65
	AC	108	67	1.03 (0.66–1.61)		1.00 (0.64–1.57)
	AA	59	27	0.76 (0.44–1.33)		0.79 (0.45–1.38)
	AC/AA	167	94	0.94 (0.62–1.41)	0.76	0.93 (0.61–1.40)	0.72
	rs6874309
	AA	228	129	1.00	0.9	1.00	0.84
	AT	36	23	1.13 (0.64–1.99)		1.19 (0.67–2.11)
	TT	3	2	1.18 (0.19–7.14)		1.08 (0.17–6.69)
	AT/TT	39	25	1.13 (0.66–1.96)	0.66	1.18 (0.68–2.05)	0.56

Recurrence and metastasis^a
Negative	rs2071165
	GG	423	208	1.00	0.86	1.00	0.76
	AG	288	148	1.05 (0.81–1.35)		1.08 (0.83–1.42)
	AA	45	20	0.90 (0.52–1.57)		0.90 (0.50–1.61)
	AG/AA	333	168	1.03 (0.80–1.32)	0.84	1.06 (0.81–1.38)	0.67
	rs4530741
	CC	124	250	1.00	0.63	1.00	0.61
	AC	181	250	1.04 (0.79–1.38)		1.00 (0.75–1.35)
	AA	71	156	0.92 (0.64–1.31)		0.9075 (0.62–1.32)
	AC/AA	252	506	1.00 (0.77–1.31)	0.98	0.9745 (0.74–1.29)	0.86
	rs6874309
	AA	310	634	1.00	0.42	1.00	0.72
	AT	64	114	1.15 (0.82–1.61)		1.07 (0.75–1.52)
	TT	2	8	0.51 (0.11–2.42)		0.7212 (0.14–3.97)
	AT/TT	66	122	1.11 (0.80–1.54)	0.55	1.05 (0.74–1.49)	0.79

Positive	rs2071165
	GG	423	167	1.00	0.75	1.00	0.97
	AG	288	102	0.90 (0.67–1.20)		0.96 (0.71–1.30)
	AA	45	18	1.01 (0.57–1.80)		0.99 (0.54–1.80)
	AG/AA	333	120	0.91 (0.69–1.20)	0.51	0.96 (0.72–1.28)	0.8
	rs4530741
	CC	99	250	1.00	0.98	1.00	0.72
	AC	138	350	0.99 (0.73–1.35)		1.06 (0.77–1.46)
	AA	49	156	0.80 (0.538–1.18)		0.80 (0.53–1.21)
	AC/AA	187	506	0.93 (0.70–1.24)	0.64	0.98 (0.73–1.32)	0.88
	rs6874309
	AA	245	634	1.00	0.63	1.00	0.41
	AT	40	114	0.91 (0.62–1.34)		0.84 (0.57–1.26)
	TT	2	8	0.65 (0.14–3.07)		0.62 (0.12–3.21)
	AT/TT	42	122	0.89 (0.61–1.30)	0.55	0.83 (0.56–1.23)	0.36

Clinical stage^a
Early	rs2071165
	GG	71	423	1.00	0.22	1.00	0.10
	AG	61	288	1.26 (0.87–1.83)		1.39 (0.94–2.05)
	AA	9	45	1.19 (0.56–2.54)		1.17 (0.53–2.57)
	AG/AA	70	333	1.25 (0.87–1.80)	0.22	1.35 (0.93–1.87)	0.12
	rs4530741
	CC	38	250	1.00	0.13	1.00	0.12
	AC	74	350	1.39 (0.91–2.12)		1.42 (0.91–2.21)
	AA	28	156	1.18 (0.70–2.00)		1.23 (0.71–2.13)
	AC/AA	102	506	1.33 (0.89–1.98)	0.17	1.36 (0.90–2.07)	0.15
	rs6874309
	AA	112	634	1.00	0.16	1.00	0.32
	AT	28	114	1.39 (0.88–2.20)		1.27 (0.79–2.06)
	TT	0	8	NA		NA
	AT/TT	28	122	1.30 (0.82–2.052)	0.26	1.2 (0.74–1.94)	0.45

Middle	rs2071165
	GG	272	423	1.00	0.43	1.00	0.62
	AG	168	288	0.91 (0.71–1.16)		0.94 (0.73–1.21)
	AA	25	45	0.86 (0.52–1.44)		0.85 (0.50–1.45)
	AG/AA	193	333	0.90 (0.71–1.14)	0.38	0.93 (0.73–1.18)	0.53
	rs4530741
	CC	166	250	1.00	0.60	1.00	0.67
	AC	217	350	0.93 (0.72–1.21)		0.94 (0.72–1.24)
	AA	82	156	0.79 (0.57–1.10)		0.77 (0.55–1.09)
	AC/AA	299	506	0.89 (0.70–1.13)	0.35	0.89 (0.69–1.15)	0.37
	rs6874309
	AA	395	634	1.00	0.73	1.00	0.49
	AT	67	114	0.94 (0.68–1.31)		0.89 (0.63–1.25)
	TT	4	8	0.80 (0.24–2.68)		0.93 (0.26–3.38)
	AT/TT	71	122	0.93 (0.68–1.28)	0.67	0.89 (0.64–1.24)	0.49

Late	rs2071165
	GG	32	423	1.00	0.77	1.00	0.98
	AG	20	288	0.92 (0.51–1.64)		1.01 (0.55–1.83)
	AA	3	45	0.88 (0.26–2.99)		0.76 (0.21–2.67)
	AG/AA	23	333	0.91 (0.52–1.59)	0.75	0.97 (0.54–1.71)	0.90
	rs4530741
	CC	19	250	1.00	0.96	1.00	0.66
	AC	27	350	1.02 (0.55–1.87)		1.15 (0.61–2.18)
	AA	9	156	0.76 (0.34–1.72)		0.90 (0.39–2.10)
	AC/AA	36	506	0.94 (0.53–1.67)	0.82	1.08 (0.59–1.97)	0.81
	rs6874309
	AA	46	634	1.00	0.82	1.00	0.88
	AT	9	114	1.09 (0.52–2.28)		0.94 (0.44–2.03)
	TT	0	8	NA		NA
	AT/TT	9	122	1.02 (0.49–2.13)	0.96	0.89 (0.41–1.91)	0.75

Tumor size^a
≥5 cm	rs2071165			1.00		1.00
	GG	423	145	1.00	0.44	1.00	0.44
	AG	288	106	1.07 (0.80–1.44)		1.14 (0.84–1.55)
	AA	45	22	1.43 (0.83–2.46)		1.40 (0.79–2.48)
	AG/AA	333	128	1.12 (0.85–1.48)	0.42	1.18 (0.88–1.58)	0.27
	rs4530741
	CC	93	250	1.00	0.86	1.00	0.69
	AC	134	350	1.03 (0.75–1.40)		1.07 (0.77–1.48)
	AA	45	156	0.78 (0.52–1.17)		0.81 (0.53–1.24)
	AC/AA	179	506	0.95 (0.71–1.27)	0.74	0.99 (0.73–1.34)	0.94
	rs6874309
	AA	239	634	1.00	0.21	1.00	0.15
	AT	33	114	0.77 (0.51–1.16)		0.73 (0.47–1.12)
	TT	1	8	0.33 (0.04–2.67)		0.37 (0.04–3.31)
	AT/TT	34	122	0.74 (0.49–1.11)	0.15	0.71 (0.46–1.08)	0.11

<5 cm	rs2071165
	GG	423	224	1.00	0.28	1.00	0.36
	AG	288	140	0.92 (0.71–1.19)		0.97 (0.74–1.27)
	AA	45	15	0.63 (0.34–1.15)		0.64 (0.34–1.20)
	AG/AA	333	155	0.88 (0.68–1.13)	0.31	0.92 (0.71–1.20)	0.55
	rs4530741
	CC	126	250	1.00	0.86	1.00	0.89
	AC	181	350	1.03 (0.78–1.36)		1.02 (0.76–1.37)
	AA	72	156	0.92 (0.64–1.30)		0.89 (0.63–1.29)
	AC/AA	253	506	0.99 (0.76–1.29)	0.95	0.98 (0.75–1.29)	0.89
	rs6874309
	AA	306	634	1.00	0.15	1.00	0.38
	AT	70	114	1.27 (0.92–1.77)		1.16 (0.83–1.64)
	TT	3	8	0.78 (0.20–2.95)		0.88 (0.21–3.66)
	AT/TT	73	122	1.24 (0.90–1.71)	0.19	1.15 (0.82–1.61)	0.42

Position^a
Cardia	rs2071165
	GG	423	78	1.00	0.14	1.00	0.34
	AG	288	39	0.73 (0.49–1.11)		0.80 (0.51–1.27)
	AA	45	7	0.84 (0.37–1.94)		0.75 (0.30–1.87)
	AG/AA	333	46	0.75 (0.51–1.11)	0.15	0.79 (0.51–1.23)	0.30
	rs4530741
	CC	38	250	1.00	0.59	1.00	0.66
	AC	60	350	1.13 (0.73–1.75)		1.12 (0.68–1.83)
	AA	27	156	1.14 (0.67–1.94)		1.38 (0.76–2.50)
	AC/AA	87	506	1.13 (0.75–1.71)	0.56	1.19 (0.75–1.89)	0.46
	rs6874309
	AA	107	634	1.00	0.66	1.00	0.25
	AT	17	114	0.88 (0.51–1.53)		0.70 (0.38–1.30)
	TT	1	2	0.74 (0.09–5.98)		0.83 (0.067–10.18)
	AT/TT	18	333	0.87 (0.51–1.49)	0.62	0.70 (0.38–1.29)	0.26

Noncardia	rs2071165
	GG	423	238	1.00	1.00	1.00	0.79
	AG	288	162	1.00 (0.78–1.28)		1.04 (0.80–1.34)
	AA	45	25	0.99 (0.59–1.65)		0.98 (0.58–1.66)
	AG/AA	333	187	1.00 (0.79–1.27)	0.99	1.03 (0.80–1.31)	0.83
	rs4530741
	CC	142	250	1.00	0.82	1.00	0.70
	AC	205	350	1.03 (0.79–1.35)		1.06 (0.80–1.40)
	AA	76	156	0.86 (0.61–1.21)		0.85 (0.60–1.21)
	AC/AA	281	506	0.98 (0.76–1.26)	0.86	0.99 (0.76–1.29)	0.95
	rs6874309
	AA	350	634	1.00	0.47	1.00	0.80
	AT	71	114	1.13 (0.82–1.56)		1.04 (0.75–1.46)
	TT	3	8	0.68 (0.18–2.58)		0.75 (0.18–3.04)
	AT/TT	74	122	1.10 (0.80–0.58)	0.56	1.03 (0.74–1.43)	0.87

¹Adjusted by gender; ²Adjusted by age and gender; ³Adjusted by age. ^aPatient numbers may not add up to 100% of available subjects because of missing clinical data.